Codexis, INC.: management transactions · United States · SEC (Form 4)

About Codexis, INC.

Codexis, Inc. (NASDAQ: CDXS) is a U.S.-based biotechnology and enzyme-engineering company headquartered in Redwood City, California, United States. The company is listed on the NASDAQ market, placing it within the U.S. public equity universe of specialized life-science small caps. Codexis was founded in 2002 and initially built itself as a platform company focused on enzyme optimization; over time, it has shifted toward higher-value pharmaceutical manufacturing applications while retaining the scientific core of its directed-evolution engine. ([codexis.com](https://www.codexis.com/about-us/history/?utm_source=openai)) At the center of Codexis’ business is its proprietary CodeEvolver® technology platform, used to discover, develop, and improve novel high-performance enzymes. Historically, the company has served pharmaceutical customers in small-molecule API and intermediate manufacturing, where engineered enzymes can help improve efficiency, selectivity, and sustainability versus more conventional chemistry routes. More recently, Codexis has sharpened its strategic focus around RNA therapeutics manufacturing, especially siRNA, through its ECO Synthesis® Manufacturing Platform. That platform is designed to support efficient, scalable enzymatic synthesis of complex RNA-based therapeutics, with particular emphasis on product quality, stereochemical control, and manufacturability. ([codexis.com](https://www.codexis.com/investors/sec-filings/annual-reports/content/0001200375-25-000003/0001200375-25-000003.pdf)) Competitive positioning is built on a combination of deep enzyme-engineering expertise, an established pharma customer base, and a differentiated value proposition around greener and potentially less capital-intensive manufacturing. Codexis addresses two overlapping markets: small-molecule pharmaceutical biocatalysis and RNAi manufacturing services/platform solutions. Management argues that many of its existing pharma relationships create a commercial bridge into RNA applications, since the same customer set is increasingly active in both small molecules and RNA therapeutics. The company’s principal competitors vary by segment, ranging from conventional chemical catalyst providers and contract manufacturers in biocatalysis to alternative RNA manufacturing approaches in the oligonucleotide space. ([codexis.com](https://www.codexis.com/investors/sec-filings/annual-reports/content/0001200375-25-000003/0001200375-25-000003.pdf)) Recent developments suggest a company in transition from research-led enzyme specialist to a more commercial therapeutics manufacturing platform. In 2025 and 2026, Codexis announced a $37.8 million technology transfer agreement with Merck, an evaluation agreement with Nitto Denko Avecia, and a contract to manufacture 50 grams of siRNA for a pharmaceutical innovator. The company also highlighted technical milestones, including larger siRNA batches and new data to be presented at TIDES USA, while pursuing an ECO GMP Manufacturing Center intended to support future scale-up, with full production capability planned by the end of 2027. For investors, Codexis remains a high-risk, technology-driven growth story whose valuation and trajectory will depend on execution, partnership conversion, and commercial adoption of ECO Synthesis. ([ir.codexis.com](https://ir.codexis.com/news-events/press-releases/detail/443/codexis-reports-fourth-quarter-and-fiscal-year-2025-financial-results))